NCT06157892 2026-03-17
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
Clinical Trials
15 trialsNCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06016387 2026-02-23
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Sunnybrook Health Sciences Centre
Phase 2 Recruiting
NCT07193394 2026-02-23
H3RAKLES
Institut Curie
Phase 2 Recruiting
NCT05458674 2026-01-12
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Criterium, Inc.
Phase 2 Recruiting
NCT04721977 2026-01-09
MK-7119-001
Pfizer
Phase 2 Active not recruiting
NCT05583110 2025-12-10
TrasTUCAN
Spanish Breast Cancer Research Group
Phase 2 Terminated
NCT05041842 2025-11-17
InTTercePT
UNICANCER
Phase 2 Active not recruiting
NCT04539938 2025-09-30
HER2CLIMB-04
Seagen Inc.
Phase 2 Completed
NCT03501979 2025-08-29
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
University of Alabama at Birmingham
Phase 2 Terminated
NCT06439693 2025-06-26
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting
NCT05748834 2025-01-31
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
SCRI Development Innovations, LLC
Phase 2 Recruiting
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT05227131 2022-07-11
MARGARET
MedSIR
Phase 2 Withdrawn